compounded semaglutide crackdown news today A secret shopper study found that the majority of weight-loss clinics and medical spas in two states offered tirzepatide and after shortages were resolved. Over half of the suppliers combined FDA warns against compounded versions

Unlike earlier-generation weight-management agents, retatrutide is a triple receptor agonist , meaning it simultaneously activates three distinct hormonal receptors: GLP-1 (glucagon-like peptide-1) receptor promotes insulin secretion, reduces appetite, and slows gastric emptying [9] [10] GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin release and may improve fat metabolism [12] [13] Glucagon receptor increases energy expenditure and may reduce hepatic steatosis, as suggested by imaging data (MRI-PDFF) from Phase 2 trials, though this effect requires confirmation in larger studies [2] [5] This triple-agonist mechanism distinguishes retatrutide from agents such as semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual agonist), and is thought to produce more pronounced reductions in body weight and improvements in metabolic parameters

A., Gaines, T

PLoS Genet 19 , e1010710 (2023)

If you ever want to stop taking Semaglutide, you and your provider can easily plan to taper off

[DOI] [PMC free article] [PubMed] [Google Scholar] 174.Ratajczak J., Joffraud M., Trammell S.A., Ras R., Canela N., Boutant M., Kulkarni S.S., Rodrigues M., Redpath P., Migaud M.E., et al

As evidence matures, it is anticipated that clinical guidelines will be developed to support safe and effective use of retatrutide, should it receive regulatory approval